Dentists in Martinsburg, PA Accepting Medicare
5 Dentists found. Showing 1 - 5
 Dr. Murray Stephen Smith, DMD Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 255 Sonoma Ln, Martinsburg, PA 16662 Phone: 814-793-2275 |
Dr. Jonathan Luke Zimmerman, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 210 E Allegheny St, Martinsburg, PA 16662 Phone: 814-793-4362 |
Dr. Paul C Hammaker, GENERAL DENTIST Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 300 S Market St, Martinsburg, PA 16662 Phone: 814-793-4475 |
Dr. Douglas C Kurtz, GENERAL DENTIST Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 300 S Market St, Martinsburg, PA 16662 Phone: 814-793-2713 |
Clark D Jeffries, GENERAL DENTIST Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 300 S Market St, Martinsburg, PA 16662 Phone: 814-793-2713 |
News Archive
First Edition: April 28, 2011
Today's headlines feature reports about the varying public responses to plans for the budget and Medicare as well as Senate Majority Leader Harry Reid's intent to bring the House-passed Ryan budget up for a vote.
Motor neurone disease neck collars: an interview with Dr Christopher J McDermott, Clinical Senior Lecturer, University of Sheffield
The majority of the current neck support collars for MND patients were designed for a different purpose. So, if you think about when people are involved in a road traffic accident, the paramedics arrive and put a collar on to immobilize the neck and protect the spine. A lot of the collars that we give to our patients with MND were actually designed for that purpose - to immobilize the necks of people involved in trauma… and patients don't want that.
Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF
Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.
New findings reveal long-term influences of infant formula composition
New findings from the Monell Center reveal that weight gain of formula-fed infants is influenced by the type of formula the infant is consuming. The findings have implications related to the infant's risk for the development of obesity, diabetes and other diseases later in life.
Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and six months ended June 30, 2010.
› Verified 5 days ago